Oral empiric treatment of community-acquired pneumonia: A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin

Chest

Volumn 110, Issue 6, 1996, Pages 1499-1506

  Örtqvist, Åke ^a   Valtonen, Matti ^d   Cars, Otto ^b   Wahl, Martin ^c   Saikku, Pekka ^e   Jean, Chantal ^f  

^a DANDERYD HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF OULU   (Finland)

^f Rhone DPC Europe   (Finland)

Author keywords

community acquired pneumonia; drug therapy; etiology

Indexed keywords

ROXITHROMYCIN; SPARFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACKACHE; BACTERIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOPLASMA PNEUMONIAE; NAUSEA; ORAL DRUG ADMINISTRATION; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; STREPTOCOCCUS PNEUMONIAE; THORAX PAIN; TREATMENT OUTCOME;

EID: 0030473476     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.110.6.1499     Document Type: Article

References (30)

1. Macfarlane J. An overview of community-acquired pneumonia with lessons learned from the British Thoracic Society study. Semin Respir Infect 1994; 9:153-65
2. British Thoracic Society. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. Q J Med New Series 1987; 62:195-220
3. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalisation: 5-year prospective study. Rev Infect Dis 1989; 11:586-99
4. Woodhead MA, Macfarlane JT. Comparative clinical and laboratory features of Legionella with pneumococcal and mycoplasmal pneumonias. Br J Dis Chest 1987; 81:133-39
5. Farr BM, Kaiser DL, Harrison BDW, et al. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. Thorax 1989; 44:1031-35
6. Fang G-D, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine 1990; 69:307-16
7. Metlay JP, Fine MJ, Lave JR, et al. Pneumonia in a 63-year-old man. J Clin Outcomes Management 1995; 2:9-24
8. Örtqvist Å., Hedlund J, Grillner L, et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalisation. Eur Respir J 1990; 3:1105-13
9. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of Oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991; 91:462-70
10. Chin NX, Gu JW, Yu KK, et al. In vitro activity of sparfloxacin. Antimicrob Agents Chemother 1991; 35:567-71
11. Örtqvist Å. Antibiotic treatment of community-acquired pneumonia in clinical practice: a European perspective. J Antimicrob Chemother 1995; 35:205-12
12. Mandell LA, Niederman M, The Canadian Community-Acquired Pneumonia Consensus Group. Antimicrobial treatment of community-acquired pneumonia in adults: a conference report. Can J Infect Dis 1993; 4:25-8
13. Niederman MS, Bass JB, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148:1418-26
14. Wang SP, Grayston JT. Micro-immunofluorescence serological studies with the TWAR organism. In: Oriel JD, Ridgeway G, Scachter J, et al, eds. Chlamydial infections. Cambridge: Cambridge University Press, 1986; 329-332
15. Jalonen E, Taira S, Paton JC, et al. Pneumolysin, produced in Bacillus subtilis as antigen in enzyme immunoassay for etiological diagnosis of pneumococcal pneumonia. Serodiagn Immunother Infect Dis 1990; 4:459-68
16. Aguero-Rosenfeld ME, Edelstein PH. Retrospective evaluation of the Du Pont radioimmunoassay kit for detection of Legionella pneumophila serogroup 1 antigenuria in humans. J Clin Microbiol 1988; 26:1775-78
17. COSTART coding symbols for thesaurus of adverse reaction terms. 3rd ed. Rockville, Md: US Dept of Health and Human Services, Food and Drug Administration, 1990
18. Jokinen C. Incidence and microbial aetiology of pneumonia in the population of four municipalities in Eastern Finland, thesis. Department of Medicine, Kuopio University Hospital, Kuopio, Finland, 1991
19. Burman LÅ, Trollfors B, Andersson B, et al. Diagnosis of pneumonia by cultures, bacterial and viral antigen detection tests, and serology, with special reference to antibodies against pneumococcal antigens. J Infect Dis 1991; 163:1087-93
20. Sundelöf B, Gnarpe J, Gnarpe H et al. Chlamydia pneumoniae in Swedish patients. Scand J Infect Dis 1993; 25:429-33
21. Kauppinen MT, Herva E, Kujala P, et al. The etiology of community-acquired pneuinonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. J Infect Dis 1995; 172:1330-35
22. Cooper BC, Mullins PR, Jones MR, et al. Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infections due to Haemophilus influenzae: a meta-analysis of 12 clinical studies. Drug Invest 1994; 7:299-314
23. Gentry LO, Rodriguez-Gomez G, Kohler RB, et al. Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization. Am Rev Respir Dis 1992; 145:31-5
24. Khan FA, Basir R. Sequential intravenous-oral administration of ciprofloxaciu vs ceftazidime in serious bacterial respiratory tract infections. Chest 1989; 96:528-37
25. Thys JP, Jacobs F, Byl B. Role of qninolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1991; 10:304-15
26. Cruciani M, Bassetti D. The fluoroquinolones as treatment for infections caused by Gram-positive bacteria. J Antimicrob Chemother 1994; 33:403-17
27. Kalager T, Andersen BM, Bergan T, et al. Ciprofloxacin versus a tobramycin/cefuroxime combination in the treatment of serious systemic infections: a prospective, randomized and controlled study of efficacy and safety. Scand J Infect Dis 1992; 24:637-46
28. Gordon JJ, Kauffman CA. Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin. Am J Med 1990; 89:383-84
29. Saito H, Kajita M, Shimokata K. Overwhelining pneumococcal pneumonia in a patient receiving ofloxacin for antimicrobial prophylaxis. Jpn J Med 1990; 29:89-90
30. Gitler B, Berger LS, Buffa SD. Torsade de pointes induced by erythromycin. Chest 1994; 105:368-72